Efficacy and Safety of AngongNiuhuang Pill for the Treatment of Patients With Acute Ischemic Stroke.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-01

Study Completion Date

2019-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AngongNiuhuang pill has obvious effects on the cardiovascular and cerebrovascular, especially the cerebral vessels. Pharmacological experiments confirmed that AngongNiuhuang pill can protect blood-brain barrier, reduce capillary permeability, improve the tolerance of cerebral ischemia and hypoxia, improve oxidative stress injury, thus protecting brain tissue. Clinical studies have also confirmed that AngongNiuhuang pill can increase the GCS score, reduce coma, improve nerve function defect and promote nerve function recovery. The primary purpose of this trial was to evaluate the effect of AngongNiuhuang pill and placebo on the improvement of life function in patients with ischemic stroke at 90 days in acute phase.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke (ANGONG TRIAL)

NCT04475328

Acute Ischemic Stroke

COMPLETED PHASE3

Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke

NCT06551727

Stroke, Ischemic

ENROLLING_BY_INVITATION NA

Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction

NCT06344312

Stroke, Acute Ischemic

ACTIVE_NOT_RECRUITING NA

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion

NCT06211712

Acute Ischemic Stroke

RECRUITING NA

Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke

NCT07163702

Acute Ischemic Stroke

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is a prospective, randomized, double-blinded, placebo parallel controlled, multiple-center trial. A total of approximately 100 patients (18 years ≤age ≤80 years) within 24 hours of symptom onset of acute ischemic stroke, who shows NIHSS from 5-20 points. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups after offering informed content: 1) one group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day; 2) the other group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.The primary purpose of this trial was to evaluate the effect of AngongNiuhuang pill and placebo on the improvement of life function in patients with ischemic stroke at 90 days in acute phase. The study consists of five visits including the day of randomization, 2-6 days, monitor daily temperature, 7 days when the therapy is done, 30 days, and 90 days when the follow-up is finished. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment neurological function rating scale will be recorded during the program. The improvement of life function will be assessed by Modified Rankin Scale(namely score=0-2). The trial is anticipated to last from July 2018 to December 2019 with 100 subjects recruited form 5 centers in China. All the related investigative organization and individuals will obey the Declaration of Helsinki and Chinese GCP standard. A Data and Safety Monitoring Board (DSMB) will regularly monitor safety during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AngongNiuhuang

Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.

Group Type EXPERIMENTAL

AngongNiuhuang pill

Intervention Type DRUG

This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.

Standard treatment

Intervention Type OTHER

The other treatments according to guidelines for standard treatment of acute ischemic stroke.

Placebo of AngongNiuhuang

Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.

Group Type PLACEBO_COMPARATOR

Placebo of AngongNiuhuang pill

Intervention Type DRUG

This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.

Standard treatment

Intervention Type OTHER

The other treatments according to guidelines for standard treatment of acute ischemic stroke.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AngongNiuhuang pill

This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.

Intervention Type DRUG

Placebo of AngongNiuhuang pill

This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.

Intervention Type DRUG

Standard treatment

The other treatments according to guidelines for standard treatment of acute ischemic stroke.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Acute ischemic stroke.
2. 18 years ≤ age ≤ 80 years.
3. Within 24 hours from symptom onset.
4. Baseline NIHSS range 5 from 20.
5. Provision of informed consent.

Exclusion Criteria

1. Not suitable for taking this medicine after dialectic of traditional Chinese medical doctor.
2. Suffering from intracranial tumors, encephalitis, subarachnoid hemorrhage and other brain organic diseases.
3. Receive thrombolysis or endovascular treatment.
4. mRS\>1 at randomization (pre-morbid historical assessment).
5. Thrombocytopenia(\<100×10\*9/L) , hematologic diseases and other systemic bleeding tendency.
6. Sleepy head (GCS≤7).
7. Alanine transaminase \> 1.5 times normal upper limit or Aspartate aminotransferase \> 1.5 times normal upper limit.
8. Glomerular filtration rate\<60 ml/min/1.73m2.
9. Patients who have been taking AngongNiuhuang pills within 3 months.
10. Pregnancy or lactation, women in childbearing age with negative pregnancy test refuse to accept contraception.
11. Participate in clinical studies of other research drugs within the last 30 days.
12. Patients with a life expectancy of less than three months.
13. Incapable to follow this study for mental illness, cognitive or emotional disorders.
14. Unsuitable for this study in the opinion of the investigators.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No